Benitec Biopharma INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Benitec Biopharma Inc. completed a registered direct offering with Averill Master Fund and Averill Madison Master Fund, selling common stock and granting registration rights for resale.
NASDAQ
SCHEDULE 13D/A: Suvretta Capital and Affiliates Increase Stake in Benitec Biopharma to 49.9% Through Direct Offering
Suvretta Capital Management and its affiliated funds, Averill Master Fund and Averill Madison Master Fund, have significantly increased their beneficial ownership in Benitec Biopharma Inc. to 49.9% following a registered direct offering.